Navigation Links
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Date:11/6/2008

SEATTLE, Nov. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today will present a summary of Phase 1 clinical data of NEUVENGE(TM) (lapuleucel-T), an investigational active cellular immunotherapy, at the Chemotherapy Foundation Symposium in New York City. The presentation, which integrates the data from two clinical trials, highlights the safety profile, immune response and clinical activity of NEUVENGE in patients with HER2/neu-positive cancer who have failed standard therapy.

"We are encouraged by the significant immune responses generated to NEUVENGE in these trials, which included patients with advanced breast, ovarian and colon cancer," said John W. Park, M.D., associate clinical professor of medicine and neurosurgery at the University of California, San Francisco. "The therapy was well tolerated and demonstrated evidence of clinical activity, with several patients experiencing prolonged periods of disease stabilization following treatment. These findings warrant further study of this promising immunotherapy."

The two Phase 1 studies (D2000-1 and D2000-2) were designed to evaluate the safety and immunologic activity of NEUVENGE in patients with metastatic HER2/neu-expressing cancer who had evidence of progressive disease following standard therapies. Patients underwent three infusions of NEUVENGE over an approximately one month period. Patients who achieved a partial response, or had stable disease lasting through Week 48, were eligible for re-treatment with a booster, using the same protocol and dose as the initial treatment.

A total of 37 patients were treated. Results from the integrated analysis showed that treatment with NEUVENGE was generally well tolerated. The majority of side effects were mild, including infusion-related fatigue, fever and chills. The median T cell proliferative stimulation index in response to the immunizing antigen increased from 1.3 at baseline to 19.7 at Week 4 (p = 0.0002), 19.4 at Week
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... According to a new market ... Market (Neurosurgical Navigation Systems, ENT Navigation Systems and Orthopedic ... Trends and Forecast, 2014 - 2020", the global surgical ... in 2013 and is expected to grow at a ... an estimated value of USD 295.5 million in 2020. ...
(Date:7/29/2014)... and NEW YORK , July ... the executive management team of Caremark Rx, Drew ... ( www.pbm365.com ).  PBM365 is the leading independent media ... reporting, insight, analysis and opinion on the pharmacy benefit ... provide insightful and timely coverage of, and context behind, ...
(Date:7/29/2014)... New York , July 29, 2014 ... by Transparency Market Research "Orthopedic Trauma Fixation Devices Market ... Analysis 2014 - 2020", the global orthopedic trauma fixation ... 2014 and is expected to grow at a CAGR ... estimated value of USD 9.3 billion in 2020. ...
Breaking Medicine Technology:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4Drew Crawford Announces Launch of PBM365 Media 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4
... OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its ... tumor cancers, announced today the submission of its Device ... Administration (FDA) for its patented OncoSec Medical System ... applicator. The Company has been developing the OncoSec Medical ...
... Reportlinker.com announces that a new market research ... Afinitor (Breast Cancer) – Analysis ... http://www.reportlinker.com/p0657207/Afinitor-Breast-Cancer-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Afinitor (Breast ... Summary ...
Cached Medicine Technology:Device Master File for OncoSec Medical System Completed and Submitted to FDA 2Device Master File for OncoSec Medical System Completed and Submitted to FDA 3Afinitor (Breast Cancer) - Analysis and Forecasts to 2020 2Afinitor (Breast Cancer) - Analysis and Forecasts to 2020 3Afinitor (Breast Cancer) - Analysis and Forecasts to 2020 4Afinitor (Breast Cancer) - Analysis and Forecasts to 2020 5Afinitor (Breast Cancer) - Analysis and Forecasts to 2020 6
(Date:7/29/2014)... Gerontological Society of America (GSA) the nation,s ... has chosen Laura N. Gitlin, PhD, of the ... the 2014 recipient of the M. Powell Lawton Award. ... in gerontology that has led to an innovation in ... or barriers, or a public policy change that has ...
(Date:7/29/2014)... 2014 CD-adapco™, the largest privately ... software, today announced its renewed membership with ... public-private partnership focused exclusively on the unique needs ... progress in the first year by bringing together ... Computational Modeling and Simulation (CM&S). This momentum will ...
(Date:7/29/2014)... Biocides are chemical substances, which are able ... growth and to prevent degradation of the physical and ... surface. It is used in various applications such as ... paints and coatings. It is also used in domestic ... in industrial applications to prevent fouling in water and ...
(Date:7/29/2014)... the federal system for financing physician training and ... billion annual investment is producing the doctors that ... the Institute of Medicine. Current financing -- ... allocates funds independent of workforce needs or educational ... in the health care settings used by most ...
(Date:7/29/2014)... July 29, 2014 Frank Davis, Activz ... can help parents add nutrition to their kids’ meals ... – Key market drivers in kids’ foods market” by ... pleased to announce the interview Frank Davis had with ... Activz organic vegetable and fruit produce powders to kids ...
Breaking Medicine News(10 mins):Health News:Gitlin earns GSA's 2014 M. Powell Lawton Award 2Health News:CD-adapco Helps Advance the Use of Simulation in Medical Device Industry 2Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 2Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 3Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 4Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 2Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 3Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 2Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 3
... BIRMINGHAM, Ala. - New clinical data showed some cancer ... called AME-133v, said a researcher at the University of ... April 15th during the 2008 annual meeting of the ... Phase 1 clinical trial data showed AME-133v had a ...
... YORK, April 16 Jenni Schaefer, a young,woman ... with anorexia and,bulimia to become a well-known motivational ... girls everywhere, has been,appointed to the Ambassador Council ... a NEDA Ambassador, Schaefer will continue her travels ...
... April 16 Natural,Nutrition, Inc. (OTC Bulletin ... InterACTIVE Nutrition, Inc. (INII), http://www.interactivenutrition.com, achieved ... in EBITDA in the three month period ... exceeded the EBITDA requirements,for the company,s senior ...
... New NCPA,Study, DALLAS, April 16 The U.S. ... workers when they work,extra hours to get ahead, according ... Policy Analysis., "The impact on low-income workers and ... Kotlikoff, Boston University,professor and author of the study. "They ...
... are doomed to fail , , WEDNESDAY, April 16 (HealthDay ... household dust? Forget about it, a new study suggests. ... found that none was effective enough in reducing exposure ... The methods looked at included using chemicals to kill ...
... SAN DIEGO As potential cancer therapies proliferate, researchers ... to more accurately predict which patients will receive the ... Research 2008 Annual Meeting, April 12-16, 2008, researchers present ... cancer, how doctors can more effectively measure response to ...
Cached Medicine News:Health News:Jenni Schaefer, Motivational Speaker, Author Named National Eating Disorders Association (NEDA) Ambassador 2Health News:Natural Nutrition Subsidiary InterACTIVE Nutrition Reports First Quarter Revenue of $4,189,048 (CDN) and EBITDA of $504,500 (CDN) 2Health News:Tax Rates Mean Extra Work Doesn't Pay 2Health News:Dust Mites Trump Asthma Prevention Guidelines 2Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 2Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 3Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 4Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 5Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 6
The CGVL vitrectomy contact glass was designed by Rol, Fankhauser et al. for photodisruptive YAG laser procedures in the posterior vitreous....
For use with Slitlamps which have a smaller distance between the eye and the reduction prism than the Haag-Streit 900. Designed to work with argon/YAG Lasers....
Advanced Corneal Topography System with integrated Keratometer. Keratometric and topographic measurements all in one instrument....
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. For newly born children. 10 mm internal diameter of the cornea ...
Medicine Products: